Corcept's quarterly revenue jumps 64% as Lifyorli sales accelerate, guidance kept
Corcept Therapeutics posted $340.5 million in third-quarter revenue, up 64% year over year, with Lifyorli adding $91.4 million. Guidance held.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Corcept Therapeutics reported third-quarter revenue of $340.5 million, up 64% year over year, according to TradingView. Lifyorli contributed $91.4 million of that total.
The company kept its fiscal 2026 revenue guidance at $1.1 billion to $1.2 billion. Management pointed to wider hypercortisolism screening, growth in oncology and several clinical catalysts ahead.
why it matters
The reaffirmed outlook and fast Lifyorli sales growth matter to investors tracking the company's newer drug. Accelerating revenue may keep interest in CORT shares elevated.
market impact
CORT shares: strong revenue growth and held guidance support the company's stock
- CORT shares pressure up — strong revenue growth and reaffirmed guidance support demand for the stock
tags
instruments
sources
- CORT: Revenue grew 64% YoY as Lifyorli uptake accelerated and guidance was reaffirmed — TradingView, 3 November 2026 at 23:57 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗